Boston Scientific (NYSE:BSX) Director Purchases $125,290.00 in Stock

Boston Scientific Corporation (NYSE:BSX) Director David Habiger acquired 2,200 shares of the stock in a transaction on Tuesday, May 19th. The stock was acquired at an average cost of $56.95 per share, for a total transaction of $125,290.00. Following the acquisition, the director directly owned 11,628 shares in the company, valued at $662,214.60. This represents a 23.33% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Boston Scientific Price Performance

Shares of BSX opened at $57.71 on Friday. Boston Scientific Corporation has a twelve month low of $52.52 and a twelve month high of $109.50. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The firm has a market capitalization of $85.77 billion, a PE ratio of 24.15, a P/E/G ratio of 1.06 and a beta of 0.62. The stock’s 50 day moving average is $61.97 and its two-hundred day moving average is $80.25.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. The company had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same period last year, the firm earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Research analysts anticipate that Boston Scientific Corporation will post 3.38 earnings per share for the current year.

Boston Scientific announced that its Board of Directors has approved a stock buyback program on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

Analyst Ratings Changes

BSX has been the topic of several research analyst reports. Royal Bank Of Canada decreased their price target on Boston Scientific from $105.00 to $100.00 and set an “outperform” rating on the stock in a research note on Thursday, April 23rd. Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. Bank of America lowered their price objective on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Canaccord Genuity Group dropped their target price on shares of Boston Scientific from $109.00 to $71.00 and set a “buy” rating for the company in a report on Thursday, April 23rd. Finally, TD Cowen cut their target price on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $92.71.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Several Boston Scientific directors bought shares this week, including Cheryl Pegus, David C. Habiger, and Edward J. Ludwig. Heavy insider buying often signals management confidence and can help support sentiment around BSX. Article Title
• Positive Sentiment: Boston Scientific’s board authorized a $5 billion share repurchase program, which can be viewed as a sign that management believes the stock may be undervalued and could provide downside support. Article Title
• Positive Sentiment: Boston Scientific recently reported earnings and revenue that slightly beat expectations and raised guidance for 2026, reinforcing the company’s longer-term growth story even though the stock has remained weak.
• Neutral Sentiment: Recent analyst commentary has been mixed: firms like Baird and Stifel still have positive ratings, but several price targets were trimmed, suggesting Wall Street remains constructive while tempering expectations. Article Title
• Negative Sentiment: Coverage asking why BSX is down 13% since its last earnings report highlights lingering investor concern that the stock has not kept pace with its fundamentals, likely weighing on near-term trading. Article Title

Institutional Investors Weigh In On Boston Scientific

A number of large investors have recently bought and sold shares of BSX. Murphy & Mullick Capital Management Corp grew its holdings in Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 170 shares during the last quarter. FWL Investment Management LLC acquired a new stake in Boston Scientific during the 2nd quarter valued at $26,000. Swiss RE Ltd. acquired a new stake in Boston Scientific during the 4th quarter valued at $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in Boston Scientific during the 4th quarter valued at $26,000. Finally, United Community Bank grew its holdings in Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 147 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.